Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT00988806
Other study ID # LAICA Study 2009
Secondary ID EudraCT 2009-011
Status Enrolling by invitation
Phase Phase 4
First received September 29, 2009
Last updated September 17, 2013
Start date November 2009
Est. completion date December 2014

Study information

Verified date September 2013
Source Hospital Universitario de Canarias
Contact n/a
Is FDA regulated No
Health authority Spain: Spanish Agency of Medicines
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the treatment strategy of long-term intermittent every 30 days, continuous intravenous infusion for 24 hours of Levosimendan, associated to optimal contemporary treatment for advanced heart failure reduce the incidence of admission for heart failure worsening at 12 months follow up, compared with the strategy based solely in the optimal contemporary treatment for advanced heart failure.


Description:

Aims: To evaluate the efficacy and safety of long-term, intermittent intravenous administration for 24 hours of Levosimendan for the treatment of advanced heart failure. Main end-point: incidence of admission due to decompensation, defined as first admission to emergency services or hospitalization more than 12 hours due to heart failure worsening.

Secondary end-points: major cardiac events, serious adverse events, change in NYHA scale at baseline, 30 days, 6 and 12 months; effects on inflammatory and neurohormonal activation in heart failure, identify factors associated with better survival of patients, quality of life, cost-effectiveness of treatment.

Study Design: Prospective, randomized, double-blind placebo controlled trial.

Scope of the study: patients with advanced heart failure.

Study Subjects: Patients over 18 years old with advanced HF of any etiology, with at least one admission for acute decompensation treated or treatable with Levosimendan within 6 months prior to randomization.

Interventions: a 24-hour infusion every 30 days of Levosimendan or placebo in addition to optimal pharmacological treatment for HF during 12 months.

Determinations: clinical monitoring, protocol-specified analytical determinations, echocardiographic assessment, invasive hemodynamic assessment, functional assessment by 6 min walk test in corridor, quality of life assessment at baseline, after 30 days, 6 months and 12 months.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 213
Est. completion date December 2014
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age over 18

- Severe symptoms of heart failure with dyspnea and/or fatigue at rest or minimal effort (functional class III and IV of NYHA)

- Episodes of fluid retention (pulmonary or systemic venous congestion, peripheral edema) and/or low cardiac output at rest (peripheral hypoperfusion)

- objective evidence of severe cardiac dysfunction determined by the presence of at least one of the following:

- Left ventricular ejection fraction </= 30%

- A severe impairment of cardiac function by echocardiography with Doppler transmitral flow pattern pseudonormal or restrictive.

- A left ventricular filling pressure elevated (PCP> 16 mmHg and / or DBP average> 12 mm Hg for pulmonary artery catheterization)

- Levels of BNP or NT-proBNP higher in the absence of noncardiac causes for this.

- Severe impairment of functional capacity as evidenced by one of the following:

- Inability to exercise

- A distance <300 m or less in women and / or patients >/= 75 years in the 6-minute walk test

- A test of myocardial oxygen consumption <12-14 ml / kg / min.

- >/= 1 prior history of HF hospitalization in the previous 6 months

- Presence of all the above criteria despite attempts to optimize therapy including diuretics, inhibitors of the renin-angiotensin-aldosterone system and beta-blockers, unless these drugs were not tolerated or were contraindicated, and cardiac resynchronization therapy when indicated.

- consent to participate in the study.

Exclusion Criteria:

- Levosimendan allergy or hypersensitivity.

- Severe renal impairment (creatinine clearance <30 ml / min).

- Severe liver impairment.

- History of autoimmune disease.

- Pregnancy.

- Women of childbearing age not using adequate contraception (hormonal, IUD, barrier + spermicide)

- Heart disease with significant obstructions to ventricular filling or emptying.

- Severe hypotension (Systolic < 90 mmHg).

- Tachycardia > 120 bpm or a history of torsion point type ventricular tachycardia.

- Severe concomitant disease with decreased short-term prognosis.

- Inability to give informed consent.

- Participation in another study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Levosimendan
Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days. Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.
Placebo
Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days. Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.

Locations

Country Name City State
Spain Department of Cardiology. Hospital Universitario de Canarias La Laguna S.C. de Tenerife

Sponsors (1)

Lead Sponsor Collaborator
Hospital Universitario de Canarias

Country where clinical trial is conducted

Spain, 

References & Publications (1)

García-González MJ, de Mora-Martín M, López-Fernández S, López-Díaz J, Martínez-Sellés M, Romero-García J, Cordero M, Lara-Padrón A, Marrero-Rodríguez F, del Mar García-Saiz M, Aldea-Perona A; LAICA study investigators. Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study. Cardiovasc Drugs Ther. 2013 Dec;27(6):573-9. doi: 10.1007/s10557-013-6476-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the incidence of admission for heart failure worsening in patients with advanced heart failure, defined as first admission to emergency services or hospitalization more than 12 hours due to a heart failure worsening. one year Yes
Secondary Time from randomization until first hospitalization for heart failure worsening. All-cause mortality. Major cardiac events. Serious adverse events. Changes in NYHA scale and quality of life of patients. To analyze the cost-effectiveness of treatment. one year Yes
See also
  Status Clinical Trial Phase
Suspended NCT02962973 - European Clinical Evaluation of the Carmat Total Artificial Heart N/A
Recruiting NCT04915924 - Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea N/A
Completed NCT01626404 - Screening for Advanced Heart Failure Treatment (SEE-HF)
Withdrawn NCT00572286 - Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study N/A
Completed NCT00690157 - Registry of Patients Referred for Heart Transplantation N/A
Active, not recruiting NCT03874312 - Ultrasound-assessed Internal Jugular Vein Distensibility in Advanced Chronic Heart Failure (US-IJVD in CHF)
Recruiting NCT05284955 - Screening for Advanced Heart Failure IN Stable outPatientS - The SAINTS Study (SAINTS B) Phase 4
Completed NCT01643551 - Neuron Specific Enolase in Ventricular Assist Device Recipients N/A
Terminated NCT04703855 - Hong Kong and Taiwan HM3 PMS N/A
Suspended NCT04851236 - Pilot Study of Massage Therapy to Improve Self Efficacy in Patients With Left-ventricular Device Early Phase 1
Recruiting NCT03526627 - Advanced Care Management in Patients With Advanced Heart Failure
Recruiting NCT06228209 - Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer N/A
Active, not recruiting NCT06259045 - Cardiac Cachexia in Advanced Heart Failure
Recruiting NCT05271214 - Conservative Management of Left Ventricular Assist Device Candidates
Recruiting NCT04475393 - Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure N/A
Recruiting NCT03919136 - Wrist Worn Blood Pressure Measurement
Recruiting NCT03911349 - Wrist Worn Blood Pressure Measurement N/A
Completed NCT01210573 - Prospective Observation of Exercise Parameters in Advanced Heart Failure N/A
Recruiting NCT04423562 - PROgnostic Value of Exercise Capacity Measured as Peak Oxygen Uptake (pVO2) in Recipients of Left Ventricular Assist Devices